Impact of diabetes on aneuploidy screening

Abstract

Maternal pregestational diabetes mellitus is a known risk factor for multiple nonchromosomal congenital anomalies, but there is no clear evidence that diabetes increases the risk for aneuploidy. However, diabetes affects maternal serum analyte concentrations that are used for aneuploidy screening and can alter the false-positive rates of the screening tests. Correction factors are used for women with pregestational diabetes for second-trimester serum analytes used in aneuploidy screening. There is considerable variation in the reported literature regarding the effect of diabetes on first-trimester serum analytes and how it might have an impact on aneuploidy screening.